ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 10,720,000 ...

"Acadia submits MAA to EMA for Rett syndrome therapy" was originally created and published by Pharmaceutical Technology, a ...

In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report), with ...

Acadia is playing for keeps. It's not just about crushing 2025 sales recordsit's about building a powerhouse. With a strong lineup of innovative therapies, a clear path to European revenues, and some ...

Analyst Jason Butler from JMP Securities reiterated a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) and keeping the price ...

Neuren's partner Acadia Pharmaceuticals submits marketing authorisation application in Europe for trofinetide for treatment ...

We recently compiled a list of the Best Medical Stocks To Buy Under $20. In this article, we are going to take a look at ...

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) was downgraded by Guggenheim from a “buy” rating to a “neutral” rating ...

ACADIA Pharmaceuticals Inc (ACAD) stock saw a modest uptick, ending the day at $18.35 which represents a slight increase of $1.66 or 9.95% from the prior close of $16.69. The stock opened at $18.24 ...

Shares of Acadia Pharmaceuticals rose after the company said it was set to join the S&P SmallCap 600 index. The biopharmaceutical company's stock jumped 12% to $18.73 in morning trading Tuesday, ...